Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X:
“One of the biggest limitations of CAR T has never been efficacy alone – it’s access.
Manufacturing delays, patient deterioration during production, and logistical complexity continue to limit who ultimately receives therapy. That’s the promise behind allogeneic ‘off-the-shelf’ CAR T. In a phase 1/2 study, CTX110 was tested in heavily pretreated patients with B-cell non-Hodgkin lymphoma:
Many had
- Primary refractory disease
- ≥3 prior lines of therapy
Yet responses were meaningful:
- ORR: 65%
- CR: 39%
And notably:
Some complete responses remained ongoing beyond 3–4 years.
Another intriguing signal:
A second CAR T infusion appeared to prolong durability.
That’s a major conceptual shift from traditional autologous CAR T, where repeat dosing is uncommon.
Toxicities were familiar:
- CRS: 54%
- ICANS: 13%
Severe events relatively limited.
Bottom line:
This study suggests off-the-shelf CAR T may be evolving from ‘rapidly available’ to ‘durably effective’.
The next frontier in cellular therapy may not just be engineering the cell but making potent therapy available before the disease outruns the patient.”
Other articles featuring Yan Leyfman on OncoDaily.